Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 1
2005 1
2008 2
2009 2
2010 2
2011 4
2012 3
2013 7
2014 9
2015 3
2016 3
2017 2
2018 5
2019 7
2020 7
2021 7
2022 9
2023 12
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

87 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for shugan zhang
Search for Shugen Zhang instead (1 results)
Chaihu-Shugan-San inhibits neuroinflammation in the treatment of post-stroke depression through the JAK/STAT3-GSK3beta/PTEN/Akt pathway.
Fan Q, Liu Y, Sheng L, Lv S, Yang L, Zhang Z, Guo J, Fan Y, Hu D. Fan Q, et al. Biomed Pharmacother. 2023 Apr;160:114385. doi: 10.1016/j.biopha.2023.114385. Epub 2023 Feb 10. Biomed Pharmacother. 2023. PMID: 36774722 Free article.
The rats were then allocated to experimental groups (n = 15) that were treated with Chaihu-Shugan-San, a JAK-STAT3 inhibitor, a GSK3beta overexpressing virus, or an empty virus (control). ...Flow cytometry showed microglia polarization towards the M1 phenotype in an in vit …
The rats were then allocated to experimental groups (n = 15) that were treated with Chaihu-Shugan-San, a JAK-STAT3 inhibitor, a GSK3b …
Shugan Jieyu Capsule in Post-Stroke Depression Treatment: From Molecules to Systems.
Zhang M, Bai X. Zhang M, et al. Front Pharmacol. 2022 Jan 24;13:821270. doi: 10.3389/fphar.2022.821270. eCollection 2022. Front Pharmacol. 2022. PMID: 35140618 Free PMC article. Review.
TCM has a very long history of being used to treat depression, and various TCM prescriptions have been clinically proven to be effective in improving depression. Among the numerous prescriptions for treating depression, Shugan Jieyu capsule (SG) is one of the classic presc …
TCM has a very long history of being used to treat depression, and various TCM prescriptions have been clinically proven to be effective in …
Clinical efficacy of Shugan granule in the treatment of mixed anxiety-depressive disorder: A multicenter, randomized, double-blind, placebo-controlled trial.
Li Y, Li L, Guo R, Yu H, Wang X, Wang B, Wang Q, Li Z, Zhao H, Temu Q, Chen X, Zhang Y, An J, Cai X, Li A, Qi L, Shang J, He H, Yang D, Lin J, Zhang Y, Zou T. Li Y, et al. J Ethnopharmacol. 2022 May 23;290:115032. doi: 10.1016/j.jep.2022.115032. Epub 2022 Jan 25. J Ethnopharmacol. 2022. PMID: 35085742 Clinical Trial.
ETHNOPHARMACOLOGICAL RELEVANCE: Shugan granule is derived from Xiaoyao powder, a traditional Chinese medicine that has been shown to be effective in treating emotional disorders. ...Subjects in the test group (n = 200) received oral administration of Shugan granules …
ETHNOPHARMACOLOGICAL RELEVANCE: Shugan granule is derived from Xiaoyao powder, a traditional Chinese medicine that has been shown to …
Different therapies of Chinese herbal medicine for diarrhea-predominant irritable bowel syndrome: A network meta-analysis of double-blinded, placebo-controlled trials.
Liu N, Li J, Wang Y, Zhang S. Liu N, et al. J Ethnopharmacol. 2023 Dec 5;317:116672. doi: 10.1016/j.jep.2023.116672. Epub 2023 Jun 14. J Ethnopharmacol. 2023. PMID: 37328079 Review.
ETHNOPHARMACOLOGICAL RELEVANCE: Shuganjianpi Therapy (SGJP), Jianpi Therapy (JP), Shugan Therapy (SG), Jianpiwenshen Therapy (JPWS), and Shuganjianpiwenshen Therapy (SGJPWS), consisting of formulas from Chinese herbal medicine (CHM), have been tremendously applied to irrit …
ETHNOPHARMACOLOGICAL RELEVANCE: Shuganjianpi Therapy (SGJP), Jianpi Therapy (JP), Shugan Therapy (SG), Jianpiwenshen Therapy (JPWS), …
Chaihu Shugan powder influences nonalcoholic fatty liver disease in rats in remodeling microRNAome and decreasing fatty acid synthesis.
Zheng C, Nie H, Pan M, Fan W, Pi D, Liang Z, Liu D, Wang F, Yang Q, Zhang Y. Zheng C, et al. J Ethnopharmacol. 2024 Jan 10;318(Pt A):116967. doi: 10.1016/j.jep.2023.116967. Epub 2023 Jul 26. J Ethnopharmacol. 2024. PMID: 37506783
ETHNOPHARMACOLOGICAL RELEVANCE: Chaihu Shugan powder (CSP) plays an important role in the prevention and treatment of nonalcoholic fatty liver disease (NAFLD) through a variety of biological mechanisms. ...
ETHNOPHARMACOLOGICAL RELEVANCE: Chaihu Shugan powder (CSP) plays an important role in the prevention and treatment of nonalcoholic fa …
Proteomics Study Reveals the Anti-Depressive Mechanisms and the Compatibility Advantage of Chaihu-Shugan-San in a Rat Model of Chronic Unpredictable Mild Stress.
Zhu X, Li T, Hu E, Duan L, Zhang C, Wang Y, Tang T, Yang Z, Fan R. Zhu X, et al. Front Pharmacol. 2022 Jan 17;12:791097. doi: 10.3389/fphar.2021.791097. eCollection 2021. Front Pharmacol. 2022. PMID: 35111057 Free PMC article.
Compared with Shu Gan and Rou Gan, the 22 Chaihu-Shugan-San advanced proteins and the affected GABA pathway may be the advantages of Chaihu-Shugan-San compatibility. This research offers data and theory support for the clinical application of Chaihu-Shugan-Sa …
Compared with Shu Gan and Rou Gan, the 22 Chaihu-Shugan-San advanced proteins and the affected GABA pathway may be the advantages of …
Herbal medicine for Hashimoto's thyroiditis: A systematic review and network meta-analysis.
Luo J, Zhou L, Sun A, Yang H, Zhang P, Liu K, Yu X, Lin Y, Huang Y, Han L. Luo J, et al. J Ethnopharmacol. 2024 Apr 6;323:117663. doi: 10.1016/j.jep.2023.117663. Epub 2024 Jan 3. J Ethnopharmacol. 2024. PMID: 38181936 Free article. Review.
Ranking probability analysis indicated that Yiqi Huayu Recipe, Liqi Xiaoying decoction, and Shugan Sanjie therapy reduced thyroid antibody levels the most, including TPOAb (100.0%, 90.9%, and 90.3%, respectively) and TGAb (98.3%, 94.4%, and 87.3%, respectively). ...
Ranking probability analysis indicated that Yiqi Huayu Recipe, Liqi Xiaoying decoction, and Shugan Sanjie therapy reduced thyroid ant …
Chaihu-Shugan-San Decoction Modulates Intestinal Microbe Dysbiosis and Alleviates Chronic Metabolic Inflammation in NAFLD Rats via the NLRP3 Inflammasome Pathway.
Liang Y, Zhang Y, Deng Y, Liang S, He Y, Chen Y, Liu C, Lin C, Han L, Tu G, Yang Q. Liang Y, et al. Evid Based Complement Alternat Med. 2018 Jul 11;2018:9390786. doi: 10.1155/2018/9390786. eCollection 2018. Evid Based Complement Alternat Med. 2018. PMID: 30105078 Free PMC article.
We evaluate the effects of the Chaihu-Shugan-San decoction on intestinal microbe dysbiosis and chronic metabolic inflammation via the NLRP3 pathway in NAFLD rats that were fed a high-fat diet. Twenty-four SD rats (male, six weeks old, 200 20 g) were randomly divided into t …
We evaluate the effects of the Chaihu-Shugan-San decoction on intestinal microbe dysbiosis and chronic metabolic inflammation via the …
Effect of Chaihu Shugan Powder-Contained Serum on Glutamate-Induced Autophagy of Interstitial Cells of Cajal in the Rat Gastric Antrum.
Tan RQ, Zhang Z, Ju J, Ling JH. Tan RQ, et al. Evid Based Complement Alternat Med. 2019 May 29;2019:7318616. doi: 10.1155/2019/7318616. eCollection 2019. Evid Based Complement Alternat Med. 2019. PMID: 31275417 Free PMC article.
Gastrointestinal (GI) motility disorder is caused by excessive autophagy of the interstitial cells of Cajal (ICC). Chaihu Shugan Powder (CSP) is a traditional Chinese medicine with therapeutic benefits in GI motility disorders; however, the underlying mechanism of its ther …
Gastrointestinal (GI) motility disorder is caused by excessive autophagy of the interstitial cells of Cajal (ICC). Chaihu Shugan Powd …
Analysis of bioactive components and synergistic action mechanism of ShuGan-QieZhi Capsule for treating non-alcoholic fatty liver disease.
Zhu T, Huang X, Zhu H, Chen J, Yao H, Zhang Y, Hua H, Zhang J, Qi J. Zhu T, et al. Phytomedicine. 2024 Jan;123:155173. doi: 10.1016/j.phymed.2023.155173. Epub 2023 Oct 29. Phytomedicine. 2024. PMID: 37976695
BACKGROUND: ShuGan-QieZhi capsule (SGQZC) is a traditional Chinese preparation used to treat hyperlipidemia and obesity, even non-alcoholic fatty liver disease (NAFLD). ...
BACKGROUND: ShuGan-QieZhi capsule (SGQZC) is a traditional Chinese preparation used to treat hyperlipidemia and obesity, even non-alc …
87 results